Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07264660 in healthy Chinese adults
NCT06712082Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2025
- Primary completion
- Sep 2025
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing PF-07264660 with Placebo (2 arms). Primary endpoints: Maximum Observed Plasma Concentration at 181 days, Time to Reach Maximum Observed Plasma Concentration at 181 days and 9 more. Started Feb 2025; status: completed.
02
Drugs
ompekimig
Beyond the preview
Go deeper on NCT06712082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06712082.